|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2004; 43:764-770, doi:10.1016/j.jacc.2003.09.051 © 2004 by the American College of Cardiology Foundation |
* Division of Pulmonary Diseases, Department of Internal Medicine I, Munich, Germany
Department of Clinical Chemistry, Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany
Manuscript received June 27, 2003; revised manuscript received September 4, 2003, accepted September 11, 2003.
* Reprint requests and correspondence: Dr. Hanno H. Leuchte, Division of Pulmonary Diseases, Department of Internal Medicine I, Ludwig Maximilians University, Klinikum Grosshadern, Munich Marchioninistr. 15, 81377 Munich, Germany.
hleuchte{at}helios.med.uni-muenchen.de
OBJECTIVES: The aim of this study was to investigate the potential role of brain natriuretic peptide (BNP) levels in the assessment of functional status and right heart performance in primary pulmonary hypertension (PPH).
BACKGROUND: Primary pulmonary hypertension is a progressive disease leading to right heart failure and death. Right heart catheterization and maximal or submaximal exercise tests are employed to assess the course of the disease and the effect of therapeutic interventions. Additional noninvasive and reproducible parameters would be helpful to assess the status of patients with PPH. The natriuretic peptide system is up-regulated in PPH patients. Brain natriuretic peptide (BNP) is produced from the cardiac ventricles and elevated in PPH. The aim of our study was to evaluate the clinical significance of BNP in PPH patients.
METHODS: Correlation analysis was performed for plasma BNP levels of 28 PPH patients and World Health Organization (WHO) functional class (WHO-class), distance walked in 6 min, peak oxygen uptake (peak VO2), and oxygen pulse during spiroergometry and various hemodynamic parameters, including pulmonary vascular resistance (PVR), pulmonary artery pressure (PAP), right atrial pressure (RAP), and cardiac index.
RESULTS: The BNP levels were inversely correlated with the 6-min walk (r = –0.70; p < 0.001) and peak VO2 (r = –0.61; p < 0.01), and positive correlation was observed with WHO-class (r = 0.79; p < 0.001). Moreover, BNP levels were also correlated to PVR (r = 0.61; p < 0.01), PAP (r = 0.48; p < 0.05), and RAP (r = 0.78; p < 0.01), and were inversely related to cardiac index (r = –0.48; p < 0.05).
CONCLUSIONS: Our data suggest that plasma BNP levels are closely related to the functional impairment of PPH patients and parallel the extent of pulmonary hemodynamic changes and right heart failure. Serial measurements of plasma BNP concentrations may help improve the management of PPH patients.
| ||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  R. W. Schrier and S. Bansal Pulmonary Hypertension, Right Ventricular Failure, and Kidney: Different from Left Ventricular Failure? Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1232 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut Surrogate and Combined End Points in Pulmonary Arterial Hypertension Proceedings of the ATS, July 15, 2008; 5(5): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A La Gerche, K A Connelly, D J Mooney, A I MacIsaac, and D L Prior Biochemical and functional abnormalities of left and right ventricular function after ultra-endurance exercise Heart, July 1, 2008; 94(7): 860 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 Circulation, June 10, 2008; 117(23): 3010 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lankeit, C. Dellas, A. Panzenbock, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schafer, M. Puls, S. Konstantinides, and I. M. Lang Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension Eur. Respir. J., May 1, 2008; 31(5): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Stolz, T. Breidthardt, M. Christ-Crain, R. Bingisser, D. Miedinger, J. Leuppi, B. Mueller, M. Tamm, and C. Mueller Use of B-Type Natriuretic Peptide in the Risk Stratification of Acute Exacerbations of COPD Chest, May 1, 2008; 133(5): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. SWANSON and M. J. KROWKA Screen for portopulmonary hypertension, especially in liver transplant candidates Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 121 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fijalkowska and A. Torbicki Role of cardiac biomarkers in assessment of RV function and prognosis in chronic pulmonary hypertension Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H41 - H47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Chin, R. N. Channick, N. H. Kim, and L. J. Rubin Central Venous Blood Oxygen Saturation Monitoring in Patients With Chronic Pulmonary Arterial Hypertension Treated With Continuous IV Epoprostenol: Correlation With Measurements of Hemodynamics and Plasma Brain Natriuretic Peptide Levels Chest, September 1, 2007; 132(3): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Edelman Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 110 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Voskaridou, G. Tsetsos, A. Tsoutsias, E. Spyropoulou, D. Christoulas, and E. Terpos Pulmonary hypertension in patients with sickle cell/{beta} thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations Haematologica, June 1, 2007; 92(6): 738 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Blyth, B. A. Groenning, P. B. Mark, T. N. Martin, J. E. Foster, T. Steedman, J. J. Morton, H. J. Dargie, and A. J. Peacock NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension Eur. Respir. J., April 1, 2007; 29(4): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. El Nounou, J. C. Tuerpe, B. Hartmann, R. A. Baumgartner, M. Vogeser, O. Muehling, and J. Behr N-terminal Pro-Brain Natriuretic Peptide and Renal Insufficiency as Predictors of Mortality in Pulmonary Hypertension Chest, February 1, 2007; 131(2): 402 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Gan, G. P. McCann, J. T. Marcus, S. A. van Wolferen, J. W. Twisk, A. Boonstra, P. E. Postmus, and A. Vonk-Noordegraaf NT-proBNP reflects right ventricular structure and function in pulmonary hypertension Eur. Respir. J., December 1, 2006; 28(6): 1190 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Voelkel, R. A. Quaife, L. A. Leinwand, R. J. Barst, M. D. McGoon, D. R. Meldrum, J. Dupuis, C. S. Long, L. J. Rubin, F. W. Smart, et al. Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure Circulation, October 24, 2006; 114(17): 1883 - 1891. [Full Text] [PDF]
|
|
|
|
|
|
S. Jelic and T. H. Le Jemtel Diagnostic Usefulness of B-Type Natriuretic Peptide and Functional Consequences of Muscle Alterations in COPD and Chronic Heart Failure. Chest, October 1, 2006; 130(4): 1220 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Machado, A. Anthi, M. H. Steinberg, D. Bonds, V. Sachdev, G. J. Kato, A. M. Taveira-DaSilva, S. K. Ballas, W. Blackwelder, X. Xu, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA, July 19, 2006; 296(3): 310 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Williams, C. E. Handler, R. Akram, C. J. Smith, C. Das, J. Smee, D. Nair, C. P. Denton, C. M. Black, and J. G. Coghlan Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur. Heart J., June 2, 2006; 27(12): 1485 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fijalkowska, M. Kurzyna, A. Torbicki, G. Szewczyk, M. Florczyk, P. Pruszczyk, and M. Szturmowicz Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension Chest, May 1, 2006; 129(5): 1313 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Leuchte, R. A. Baumgartner, M. E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, and J. Behr Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mahapatra, R. A. Nishimura, P. Sorajja, S. Cha, and M. D. McGoon Relationship of Pulmonary Arterial Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., February 21, 2006; 47(4): 799 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Klinger, S. Thaker, J. Houtchens, I. R. Preston, N. S. Hill, and H. W. Farber Pulmonary hemodynamic responses to brain natriuretic Peptide and sildenafil in patients with pulmonary arterial hypertension. Chest, February 1, 2006; 129(2): 417 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur. Respir. J., November 1, 2005; 26(5): 858 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, C. Neurohr, M. Vogeser, and J. Behr Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2368 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bonderman, R. Nowotny, N. Skoro-Sajer, J. Jakowitsch, C. Adlbrecht, W. Klepetko, and I. M. Lang Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension Chest, October 1, 2005; 128(4): 2599 - 2603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Piazza and S. Z. Goldhaber The Acutely Decompensated Right Ventricle: Pathways for Diagnosis and Management Chest, September 1, 2005; 128(3): 1836 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mockel, R. Muller, J. O. Vollert, C. Muller, A. Carl, D. Peetz, F. Post, J. K. Kohse, and K. J. Lackner Role of N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification in Patients Presenting in the Emergency Room Clin. Chem., September 1, 2005; 51(9): 1624 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen, C. W. Hamm, V. Mitrovic, N.-H. Lantelme, H. D. White, and for the Platelet Receptor Inhibition in Ischemic S N-Terminal Pro-B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes Circulation, November 16, 2004; 110(20): 3206 - 3212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Hill Brain Natriuretic Peptide: Is It Helpful in Detecting Pulmonary Hypertension in Fibrotic Lung Disease? Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 352 - 353. [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sharp and J. Mayet Review: The utility of BNP in clinical practice Journal of Renin-Angiotensin-Aldosterone System, June 1, 2004; 5(2): 53 - 58. [Abstract] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
